Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of MABT5102A in patients with Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• MABT5102A (MABT5102A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED